GLP-1 drugs: do they really change what you crave?
NCT ID NCT06467604
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at how popular weight-loss drugs like semaglutide and tirzepatide affect food cravings and diet quality in people with obesity. Over 24 weeks, participants fill out surveys and food diaries to track changes. The goal is to understand whether these medications improve eating habits, not just reduce weight.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GLP-1 receptor agonists (semaglutide and tirzepatide)
- What this could lead to
- If successful, this study could help doctors understand how GLP-1 drugs change eating habits and cravings, leading to better dietary advice for patients.
- What could go wrong
- This is a small observational study with only 7 participants, so results may not apply to everyone. It does not test new treatments or cures.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Knownwell
Needham, Massachusetts, 02492, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?